GlassScriptPhysician profile
Vahid Osman
NPI 1740264720
$4,529.74
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $972 · 2020: $901 · 2021: $1,709 · 2022: $600 · 2023: $249 · 2024: $98.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $301 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $300.52 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $517.17 | 2019-2023 | Spravato |
| Vanda Pharmaceuticals INC. | $405.59 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $405.03 | 2019-2023 | Trintellix |
| Abbvie INC. | $387.52 | 2021-2024 | |
| Adlon Therapeutics L.P. | $335.62 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $262.94 | 2019-2023 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $262.63 | 2019-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $239.17 | 2019-2021 | |
| Lundbeck LLC | $219.57 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $207.83 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $201.72 | 2020-2023 | |
| Eisai INC. | $197.43 | 2020-2021 | |
| Allergan, INC. | $155.84 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $91.28 | 2021-2023 | Qelbree |
| Ironshore Pharmaceuticals INC. | $91.06 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $90.51 | 2019-2021 | |
| Neos Therapeutics, LP | $85.72 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $79.61 | 2019-2021 | |
| Alkermes, INC. | $77.71 | 2019-2022 | |
| Shire North American Group INC | $57.22 | 2019 | |
| Corium, LLC | $46.84 | 2022-2023 | Azstarys |
| Brainsway USA INC | $39.85 | 2019 | |
| Bausch Health US, LLC | $34.06 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $14.81 | 2021 | |
| Orexo US, INC. | $12.68 | 2020 | |
| Neuronetics, INC. | $10.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vahid Osman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.